Stem Cells FIX Fetus Spines—Unbelievable!

Close-up of a spine model highlighting the vertebrae and spinal cord

Doctors reversed brain damage in unborn babies using stem cells applied directly to their spines, a breakthrough that could rewrite the future for families facing spina bifida.

Story Highlights

Six fetuses received placenta-derived stem cells during surgery at 24-25 weeks gestation, fully reversing hindbrain herniation confirmed by post-birth MRIs.
No infections, tumors, or serious adverse effects occurred; all babies born with intact spinal repairs between July 2021 and December 2022.
First human trial combining fetal surgery with live stem cells, surpassing the 2011 MOMS trial’s limits on brain and motor neuron repair.
Phase 2 trial now enrolling 35 patients to test efficacy, with long-term follow-ups to age 6 underway.
Promises scalable platform to cut lifelong disability costs and boost quality of life for spina bifida cases.

Spina Bifida’s Devastating Toll

Myelomeningocele, the severest spina bifida form, strikes about 1 in 1,000 UK births. It triggers paralysis, incontinence, leg sensory loss, scoliosis, and hindbrain herniation known as Chiari II malformation. This herniation causes hydrocephalus and learning disabilities. Families endure lifelong challenges. Prior treatments offered partial relief, but core nerve damage persisted. California researchers targeted this gap head-on with innovative in-utero intervention.

Pioneering Fetal Surgery Meets Stem Cells

Surgeons operated on pregnancies at 24-25 weeks gestation. They exposed the spinal cord defect during fetal surgery, then applied placenta-derived mesenchymal stem cells directly. These PMSCs, sourced from donated placentas, provide anti-inflammatory, neuroprotective, and regenerative effects. Animal models validated this approach first. The team sealed the defect afterward. Babies delivered normally from July 2021 to December 2022 with no complications.

Post-birth MRIs revealed complete hindbrain herniation reversal in every case. No abnormal growth or infections appeared. This marked the first human delivery of live stem cells to a fetal spinal cord. Unlike the MOMS trial, which cut shunt needs and boosted leg function but left motor neuron damage untouched, this method addressed brain issues directly. Conservative values celebrate such life-affirming science that protects the unborn and empowers families.

Safety Confirmed in Phase 1 Trial

The Lancet published phase 1 results around February 2026. Researchers tracked zero serious adverse effects. PMSCs integrated safely, promoting nerve healing and reducing inflammation. Babies now receive routine care with monitoring to age 6 for mobility and safety data. Uniform expert optimism prevails, though all stress larger trials for efficacy proof. Facts align solidly; small sample suits phase 1’s safety focus perfectly.

Researchers hailed it as a scalable platform to alter lifelong health trajectories. This milestone paves ways for treating other congenital conditions. Regulatory bodies greenlit phase 2, enrolling 35 patients. Academic-medical teams standardize biologics delivery workflows. ISSCR oversees stem cell ethics rigorously.

Path Forward and Broader Promise

Short-term, safety data unlocks phase 2 and 3 trials. Long-term, it could redefine spina bifida care, slashing shunt dependency, enhancing mobility, and easing chronic burdens. Affected families—facing 1-in-1,000 odds—stand to gain most. Economic savings from reduced disability costs benefit society. Politically, it advances fetal therapy rules sensibly.

Regenerative medicine surges ahead. In-utero biologics now viable for defects beyond spina bifida. UC Davis-linked teams drive this progress. Common sense demands swift, ethical expansion—prioritizing proven safety while verifying outcomes. Families deserve these tools to thrive, not just survive.